LLY · SPRB 10-KMar 9 '26
“License Agreement with Eli Lilly and Company In May 2016, we entered into a license agreement (the "Lilly License Agreement") with Eli Lilly and Company ("Lilly").”
BMRN · SPRB 10-KMar 9 '26
“we acquired, among other things, that certain Exclusive License Agreement, by and between BioMarin Pharmaceutical Inc. ("BioMarin")”
LLY · CAMP 10-KMar 5 '26
“During the years ended December 31, 2025 and 2024, we recorded $0.1 million and $0.5 million, respectively, as a reduction in R&D expense in the consolidated statement of operations and comprehensive loss as a result of the earned R&D reimbursement from Eli Lilly.”
BMRN · CAMP 10-KMar 5 '26
“Under the terms of the BioMarin Agreement, BioMarin paid us an upfront, nonrefundable payment of $1.0 million, and reimbursed us for certain research activities.”